Scott McCallister

4.1k total citations · 1 hit paper
54 papers, 2.1k citations indexed

About

Scott McCallister is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Scott McCallister has authored 54 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Infectious Diseases, 29 papers in Virology and 18 papers in Emergency Medicine. Recurrent topics in Scott McCallister's work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (29 papers). Scott McCallister is often cited by papers focused on HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (29 papers) and HIV/AIDS Research and Interventions (29 papers). Scott McCallister collaborates with scholars based in United States, United Kingdom and Spain. Scott McCallister's co-authors include Robertino M. Mera, Patrick S. Sullivan, Amanda D. Castel, Aaron J. Siegler, Michael R. Kramer, Elizabeth Pembleton, Farah Mouhanna, Jeb Jones, Jodie L. Guest and Christian Callebaut and has published in prestigious journals such as Annals of Internal Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Scott McCallister

54 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States

2018 310 citations Aaron J. Siegler, Farah Mouhanna et al. Annals of Epidemiology profile →

Peers

Scott McCallister

EPIDE

VIROL

HEPAT

Michelle E. Roland United States

AN Phillips United Kingdom

Inmaculada Jarrín Spain

C. William Wester United States

Anders Blaxhult Sweden

Nagalingeswaran Kumarasamy India

François Dabis France

Kathleen C. Wood United States

Clemens Richter Netherlands

Michelle E. Roland United States

Scott McCallister

2.1k ×1.2

1.4k ×1.5

EPIDE

790 ×1.1

VIROL

601 ×1.4

539 ×1.7

HEPAT

Citations per year, relative to Scott McCallister Scott McCallister (= 1×) peers Michelle E. Roland

Countries citing papers authored by Scott McCallister

Since Specialization

Citations

This map shows the geographic impact of Scott McCallister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott McCallister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott McCallister more than expected).

Fields of papers citing papers by Scott McCallister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott McCallister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott McCallister. The network helps show where Scott McCallister may publish in the future.

Co-authorship network of co-authors of Scott McCallister

This figure shows the co-authorship network connecting the top 25 collaborators of Scott McCallister. A scholar is included among the top collaborators of Scott McCallister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott McCallister. Scott McCallister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vannappagari, Vani, Scott McCallister, Mark Bush, et al.. (2024). Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV. Infectious Diseases and Therapy. 13(7). 1391–1398. 3 indexed citations

Sullivan, Patrick S., Farah Mouhanna, Robertino M. Mera, et al.. (2020). Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions. Annals of Epidemiology. 44. 16–30. 27 indexed citations

Siegler, Aaron J., C. Christina Mehta, Farah Mouhanna, et al.. (2020). Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. Annals of Epidemiology. 45. 24–31.e3. 66 indexed citations

Sullivan, Patrick S., Robertino M. Mera, Farah Mouhanna, et al.. (2018). Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Annals of Epidemiology. 28(12). 833–840. 165 indexed citations

Margot, Nicolas, Stephanie Cox, Moupali Das, et al.. (2018). Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks. Journal of Clinical Virology. 103. 37–42. 16 indexed citations

DeJesus, Edwin, Sorana Segal‐Maurer, Moti Ramgopal, et al.. (2018). Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Research and Human Retroviruses. 34(4). 337–342. 67 indexed citations

Siegler, Aaron J., Farah Mouhanna, Robertino M. Mera, et al.. (2018). The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States. Annals of Epidemiology. 28(12). 841–849. 310 indexed citations breakdown →

Funderburg, Nicholas, Grace A. McComsey, Manjusha Kulkarni, et al.. (2016). Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 13. 321–327. 19 indexed citations

DeJesus, Edwin, Anton Pozniak, Melanie Thompson, et al.. (2015). P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations

10.

Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2015). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(5). 530–537. 158 indexed citations

11.

Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445. 121 indexed citations

12.

Garner, Will, et al.. (2015). Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials. Clinical Infectious Diseases. 62(7). 929–934. 2 indexed citations

13.

Sax, Paul E., Andrew Zolopa, Indira Brar, et al.. (2014). Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(1). 52–58. 165 indexed citations

14.

Richards, John H. & Scott McCallister. (2008). Maturation inhibitors as new antiretroviral agents.. PubMed. 13(4). 79–82. 2 indexed citations

15.

Markowitz, Martin, Leonard N. Slater, Robert A. Schwartz, et al.. (2007). Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes. 45(4). 401–410. 16 indexed citations

16.

Gathe, Joseph, David A. Cooper, Charles Farthing, et al.. (2006). Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial. Clinical Infectious Diseases. 43(10). 1337–1346. 67 indexed citations

17.

MacGregor, Thomas R., et al.. (2004). Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers. HIV Clinical Trials. 5(6). 371–382. 55 indexed citations

18.

Patterson, Bruce K., Scott McCallister, Malte Schütz, et al.. (2001). Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 15(13). 1635–1641. 43 indexed citations

19.

Linnemeier, Thomas J., Scott McCallister, Daniel Lips, et al.. (1993). Radiation exposure: Comparison of rapid exchange and conventional over‐the‐wire coronary angioplasty systems. Catheterization and Cardiovascular Diagnosis. 30(1). 11–14. 10 indexed citations

20.

Taliercio, Charles P., Scott McCallister, David R. Holmes, Duane M. Ilstrup, & Ronald E. Vlietstra. (1989). Nephrotoxicity of nonionic contrast media after cardiac angiography. The American Journal of Cardiology. 64(12). 815–816. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact